Company Profile
ImmunoGen Stock Price, News & Analysis
- Ticker:
- IMGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for IMGN.
Company overview
Business overview
ImmunoGen was an antibody-drug conjugate company focused on oncology before being acquired by AbbVie.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in oncology biotechnology.
Business Model Characteristics
The business was driven by ADC development, commercial execution, and the value of its tumor-targeting payload platform.
Position Within the Biotechnology Landscape
ImmunoGen was one of the defining ADC names and now belongs to biotech M&A history.
Future catalysts
ImmunoGen is now mainly a closeout / integration story after the AbbVie transaction, so the catalysts are any remaining corporate or settlement steps rather than a live pipeline event. The market is focused on residual value and final integration details.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does ImmunoGen do?
ImmunoGen was an antibody-drug conjugate company focused on oncology before being acquired by AbbVie.
On which exchange is IMGN stock listed?
ImmunoGen (IMGN) is associated with NASDAQ, United States, Biopharma.
What is ImmunoGen?
ImmunoGen is now mainly a closeout / integration story after the AbbVie transaction, so the catalysts are any remaining corporate or settlement steps rather than a live pipeline event.
Which conditions is ImmunoGen targeting with ImmunoGen?
ImmunoGen is associated with oncology based on its company overview and current catalyst commentary.
How does ImmunoGen describe recent progress with ImmunoGen?
ImmunoGen is now mainly a closeout / integration story after the AbbVie transaction, so the catalysts are any remaining corporate or settlement steps rather than a live pipeline event.
What is AbbVie?
ImmunoGen was an antibody-drug conjugate company focused on oncology before being acquired by AbbVie.
What should investors watch for with AbbVie?
ImmunoGen is now mainly a closeout / integration story after the AbbVie transaction, so the catalysts are any remaining corporate or settlement steps rather than a live pipeline event.
What future catalysts are investors watching for ImmunoGen?
ImmunoGen is now mainly a closeout / integration story after the AbbVie transaction, so the catalysts are any remaining corporate or settlement steps rather than a live pipeline event. The market is focused on residual value and final integration details.